Metastatic hormone-sensitive prostate cancer with visceral involvement (lung and liver) after prostatectomy
This presentation indicates metastatic prostate adenocarcinoma with biochemical recurrence following radical prostatectomy and subsequent radiographic spread to lung and liver. Definitive management is systemic therapy with androgen deprivation therapy (ADT) plus an intensification agent appropriate for metastatic hormone-sensitive prostate cancer (mHSPC), with local therapy to the prostate reserved for selected palliation rather than as a curative strategy in typical visceral high-burden disease ASCO GU 2023 guideline update, [1], [2].
Pathophysiologic mechanism of malignant transformation and impact on serum PSA
Prostate adenocarcinoma arises from malignant transformation of prostatic epithelial cells that acquire genetic and epigenetic alterations enabling androgen-driven proliferation and loss of normal glandular differentiation. Tumor cells frequently retain androgen receptor signaling and express PSA (KLK3) under androgen regulation, so serum PSA typically reflects tumor burden and androgen-receptor activity rather than the normal function of benign prostatic tissue. When metastatic lesions develop, PSA secretion commonly persists, leading to increasing PSA after prostatectomy if PSA-producing malignant cells remain or re-emerge.
Clinical symptoms supporting metastatic disease diagnosis
Metastatic prostate cancer may present with systemic and organ-specific manifestations. Visceral metastases commonly support the diagnosis when symptoms or findings include:
- Constitutional symptoms such as fatigue or weight loss.
- Respiratory symptoms compatible with lung involvement, including cough or dyspnea.
- Hepatic symptoms compatible with liver involvement, including right upper quadrant discomfort, jaundice, or laboratory cholestatic abnormalities.
Radiographically confirmed lung and liver metastases provide direct anatomic evidence supporting metastatic disease in this case.
PSA utilization for screening, diagnosis, and monitoring
Screening
Population screening uses PSA in shared decision-making for men at typical screening ages.
- Men aged 55 to 69 years: shared decision-making for PSA screening is recommended by USPSTF [3].
- AUA early detection: PSA is the primary screening modality, with shared decision-making emphasized and recommended screening intervals individualized based on PSA level and risk [4], AUA/SUO Part I (Journal of Urology).
Diagnosis after prostatectomy (biochemical recurrence)
After radical prostatectomy, serum PSA is used to detect residual or recurrent disease because benign prostate tissue is removed. Rising PSA after prostatectomy supports biochemical recurrence and triggers evaluation for local recurrence and metastases.
Monitoring during systemic therapy
PSA is used for longitudinal response assessment during ADT-based therapy:
- Declining PSA supports biochemical response.
- Rising PSA on therapy supports progressive disease, typically prompting reassessment with imaging and consideration of change in systemic regimen.
Staging and grading (Gleason scoring and grade groups)
Pathologic grade
The final prostatectomy pathology provided Gleason 8 (4+4). In AJCC 8th edition, grade groups are mapped to Gleason patterns, where Grade Group 4 corresponds to Gleason sum 8 [5], AJCC staging form supplement.
Clinical stage with visceral metastases
With radiographically confirmed lung and liver metastases, the metastatic category is M1. AJCC uses M category definitions to represent distant metastasis presence, and visceral organ metastases qualify for distant metastatic disease [5], AJCC staging form supplement.
Major prognostic factors and influence on outcome
Key prognostic drivers in mHSPC include:
- Extent of metastatic burden. High metastatic burden is associated with worse outcomes than low metastatic burden and is used for treatment stratification in major trials [2].
- Tumor grade. Higher-grade disease (e.g., Gleason 8) is associated with more aggressive biology and higher risk of progression [5].
- Disease distribution including visceral metastases. Visceral metastases are classified within high metastatic burden in STAMPEDE [2].
- Performance status and chemotherapy fitness. Selection between triplet/ADT intensification strategies depends partly on chemotherapy candidacy as reflected in guideline recommendations ASCO GU guideline update.
Risk category and appropriate definitive local therapy
Risk category
Visceral metastases (lung and liver) support high-volume / high-burden mHSPC, consistent with trial definitions where visceral metastases fall into high metastatic burden [2].
Definitive local therapy
In typical visceral high-burden metastatic presentations, curative-intent definitive local therapy to the prostate is not standard, and management prioritizes systemic treatment. Local prostate-directed therapy (radiotherapy) may be considered for palliation rather than definitive cure in high-burden disease ASCO GU guideline update, [2].
Systemic treatment regimens for metastatic hormone-sensitive prostate cancer with visceral involvement
Core principle
For metastatic noncastrate prostate cancer, ADT-based intensification is recommended over ADT alone, using either:
- ADT + docetaxel for appropriate chemotherapy candidates.
- ADT + an androgen receptor pathway inhibitor (ARPI) for patients selected for nonchemotherapy intensification.
- ADT + ARPI + docetaxel (triplet) for patients eligible for all components per guideline recommendations ASCO GU 2023 guideline update.
Recommended regimen options (with specific drugs and dosing)
1) ADT + docetaxel (chemohormonal doublet)
- Docetaxel: 75 mg/m² IV every 3 weeks for up to 6 cycles in metastatic hormone-sensitive settings in major trials and guideline-based regimens [1], ASCO guideline update, Urology/EAU treatment summary referencing standard dosing.
- ADT backbone: an LHRH agonist or antagonist is used to achieve castrate testosterone, with continuation during systemic therapy. (ADT formulation selection is individualized and not dose-specified here because multiple equivalent approaches exist across formularies and local practice.)
Supporting evidence includes survival benefit from early docetaxel addition to ADT in CHAARTED and STAMPEDE trial programs [1], [2].
2) ADT + abiraterone acetate + prednisone (ARPI doublet)
- Abiraterone acetate: 1,000 mg orally once daily.
- Prednisone: dosing paired with abiraterone as specified by labeling for metastatic castration-sensitive disease regimens varies by approved label language; for metastatic castration-resistant disease labeling, prednisone is 5 mg orally twice daily [6].
- Selection of the exact prednisone schedule should follow the specific mCSPC labeling used in practice settings and local pharmacy protocols [6].
Evidence base for ADT + abiraterone improving outcomes in mHSPC includes randomized trials summarized in metastatic hormone-sensitive systemic therapy literature [7].
3) ADT + enzalutamide (ARPI doublet)
- Enzalutamide: 160 mg orally once daily with or without food [8].
Evidence base includes phase 3 studies demonstrating improved outcomes with enzalutamide plus ADT in metastatic hormone-sensitive disease as reflected by guideline updates ASCO GU guideline update.
4) ADT + ARPI + docetaxel (triplet therapy)
Triplet therapy is recommended for appropriately selected patients who can receive chemotherapy and an ARPI.
- Darolutamide triplet: darolutamide 600 mg twice daily in combination with ADT + docetaxel has been investigated in ARASENS [9], and docetaxel dosing aligns with standard 75 mg/m² every 3 weeks schedules in this setting ASCO guideline context, [10].
- Guideline updates support offering triplet therapy with darolutamide + ADT and docetaxel for suitable patients ASCO guideline update, [10].
Supporting evidence and treatment selection logic
- High metastatic burden includes visceral metastases [2].
- Docetaxel + ADT improves outcomes in mHSPC, including high-burden subgroups assessed in CHAARTED programs [1].
- Guideline recommendations endorse intensified systemic therapy beyond ADT alone, with treatment choice reflecting chemotherapy eligibility and tolerability ASCO GU 2023 guideline update.